its phase III study DIAGNODE-3. Earlier this year, the company signed a collaboration agreement with the research organization JDRF and is now in the process of a rights issue of SEK 243 million. CEO Ulf Hannelius explains more in a company presentation at BioStock.
Se Diamyd Medicals vd Ulf Hannelius present the company in advance.
This material has been prepared for marketing purposes and is not and shall not be considered to constitute a prospectus under applicable laws and regulations. The full terms and conditions of the rights issue and further information about the company have been set out in a prospectus which was published and published on diamyd.com on October 16, 2023.